.tb-field[data-toolset-blocks-field="61a62dbe40a1c7b53ae057ddc5b5095c"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="677fdf1d8063c5ed296b59b9575b5234"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

Neogap secures SEK 87 million to advance clinical development of its personalised immunotherapy

11 February 2026 -- Solna, Sweden -- Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has raised SEK 87 million in a financing round led...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2026

Neogap Therapeutics

info@neogap.se

Stiftelsen Cancercentrum Karolinska (CCK) Visionsgatan 56 171 64 Solna, Sweden

Levicept Announces the Appointment of James Sandy as Chief Development Officer

Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis 4 February 2026 -- Sandwich, UK -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 4, 2026

Levicept

info@levicept.com

Innovation House Discovery Park Ramsgate Road Sandwich Kent CT13 9ND

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments 8 October 2025 -- New York, New York...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Nilo Therapeutics

info@nilotx.com

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

Financing supports execution of early-stage clinical trials for Anocca’s lead programme VIDAR-1, powered by the Company’s leading-edge R&D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: August 18, 2025

Anocca

info@anocca.com

Forskargatan 20C 151 36 Södertälje, Sweden

ACG to Showcase Sustainable Packaging Innovations at Pharmapack Paris 2025

Welcomes Jochen Scheil as Head of Global Sales for ACG Packaging Materials 21 January 2025 -- Paris, France -- ACG, the world’s leading supplier of integrated solutions for the pharmaceutical...

Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 21, 2025

ACG World

D Bhabrekar Nagar Road Mumbai, Maharashtra 400067, IN

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of...

Category: Drug Discovery
Posted: January 17, 2025

Owlstone Medical

breathbiopsy@owlstone.co.uk

Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK

DeanHouston Appoints New Director of Hygienic Markets

Jeff Blease brings more than 31 years of industry experience 8 January 2025 -- Kentucky, US -- DeanHouston, a business-first marketing firm that excels at creating meaningful communication strategies for...

Category: Other
Posted: January 8, 2025

DeanHouston

cincinnati@deanhouston.com

525 Scott Street Suite 201 Covington, KY 41011

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors

Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership Valiltramiprosate/ALZ-801 Has Potential to Become the First Oral Agent to Slow Alzheimer’s Pathology in Patients APOLLOE4 Pivotal Phase...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 7, 2025

Alzheon

111 Speen Street, Suite 306 Framingham, MA 01701

IDDI Announces New Leadership to Drive Growth and Innovation

Tim Davis appointed as new Chief Executive Officer and Jeremy Edwards named the new Chief Commercial Officer 7 January 2025 -- Ottignies, Belgium -- International Drug Development Institute (IDDI), a...

Category: Clinical Trials, Other, Pharmaceutical
Posted: January 7, 2025

IDDI

info@iddi.com

Avenue Provinciale, 30 1341 Ottignies-Louvain-la-Neuve Belgium

CluePoints Appoints Richard Young as Chief Strategy Officer

28 October 2024 -- Pennsylvania, US -- RBQM innovator CluePoints has today announced that Richard Young has been appointed as its new Chief Strategy Officer. With 30 years of experience...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 28, 2024

CluePoints

contact@cluepoints.com

1000 Continental Drive, Suite 240, King of Prussia, PA 19406

Coronado Research Limited announce appointment of Professor Jennifer Visser-Rogers as Chief Scientific Officer

24 October 2024 -- London, UK -- Coronado Research announced today that Professor Jennifer Visser-Rogers has been appointed as Chief Scientific Officer. Jennifer brings with her a broad portfolio of...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 24, 2024

Coronado Research

datadriven@coronado-research.com

3PBIOVIAN strengthens its leadership team with the appointment of a Business Development Director for Advanced Therapies

This strategic hire will further solidify 3PBIOVIAN’s position as a leading CDMO in the development of advanced therapies and enhance its international commercial team 9 October 2024 -- Noáin, Spain...

Category: Drug Delivery, Other, Pharmaceutical
Posted: October 9, 2024

3PBiovian

Mosaic Therapeutics appoints Dr Barry Davies as CSO

Former AstraZeneca Senior Director, Global Project Leader adds significant experience and expertise to leadership team Appointment will drive further development of Mosaic’s targeted oncology combination therapies pipeline and platform. 7...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 7, 2024

Mosaic Therapeutics

info@mosaic-tx.com

Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR

Coronado Research announce engagement of Rob Nichols to support the growth of their Clinical Technology Practice

3 October 2024 -- London, UK -- Coronado Research announced the engagement of Rob Nichols to support the build-out of its clinical technology practice and advise the executive leadership team...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 3, 2024

Coronado Research

datadriven@coronado-research.com

ProPharma Names Dawn Sherman Chief Executive Officer

Veteran life sciences and biopharmaceutical industry executive previously served as ProPharma CEO 1 October 2024 -- North Carolina, US -- ProPharma, the leading global provider of regulatory, clinical, and compliance...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: October 1, 2024